title: Biologic effects of recombinant human interleukin-3 in vivo.
abstract: The biologic in vivo effects of recombinant human interleukin-3 (rhIL-3) were assessed in a phase I clinical study of 30 patients with advanced malignancy. On day 1 rhIL-3 was administered by a single intravenous (IV) bolus injection, followed by subcutaneous (SC) injections once daily from day 2 to 15; at least three patients were treated at each dose level (60, 125, 250, and 500 micrograms/m2). A transient decrease of eosinophil and monocyte counts was observed immediately after IV injection of rhIL-3, whereas the neutrophil count remained unaffected. Total WBC counts and neutrophil counts increased dose dependently up to threefold, whereas a 10-fold to 50-fold rise was observed in levels of circulating eosinophils and basophils. Platelet counts increased up to twofold. Patients developed moderate increases of serum levels of soluble interleukin-2 receptors, beta 2-microglobin, and immunoglobulin M (IgM), and of the acute phase reactants, C-reactive protein (CRP), fibrinogen, and haptoglobin. An increase in interleukin-6 (IL-6) serum levels was detected in patients treated by IV bolus rhIL-3. The serum half-life of IV injected rhIL-3 was 20 +/- 3 minutes; after SC administration, 210 +/- 15 minutes. Administration of rhIL-3 was generally well tolerated, with mild fever, headache, and local reactions at the injection site being the most frequent side effects. The primary course of the underlying malignant diseases was not significantly altered by administration of rhIL-3. The results indicate that rhIL-3 acts in vivo as a multilineage hematopoietic growth factor and a weak inflammatory mediator that may be used successfully to improve states of hematopoietic failure.
authors.affiliation: Department of Internal Medicine I, University of Freiburg, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Lindemann
authors.forename: A
authors.initials: A
authors.lastname: Ganser
authors.forename: F
authors.initials: F
authors.lastname: Herrmann
authors.forename: J
authors.initials: J
authors.lastname: Frisch
authors.forename: G
authors.initials: G
authors.lastname: Seipelt
authors.forename: G
authors.initials: G
authors.lastname: Schulz
authors.forename: D
authors.initials: D
authors.lastname: Hoelzer
authors.forename: R
authors.initials: R
authors.lastname: Mertelsmann
mesh_terms: D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004797:Enzyme-Linked Immunosorbent Assay; D004804:Eosinophils / Q000187:drug effects; D005260:Female; D006801:Humans; D007377:Interleukin-3 / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D010976:Platelet Count / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D007377:Interleukin-3; D011994:Recombinant Proteins